Interviews

Phase 2 trial tests azacitidine plus venetoclax in therapy-related high-risk MDS, showing remissions and better post-transplant survival despite TP53 mutations.

Clinicians explore the shift towards earlier use of antibody-drug conjugates in GI oncology, aiming to enhance patient outcomes and treatment efficacy.

TNBC care shifts to TROP2 ADCs plus immunotherapy, highlighting early relapse needs, sequencing dilem

During his presentation at the 4th Annual Miami Cancer Institute Precision Oncology Symposium, Petros Grivas, MD, PhD, FASCO, provided a detailed roadmap for community oncologists with an emphasis on precision medicine.

Recent trials reveal promising advancements in targeted therapies for chondrosarcomas and tenosynovial giant cell tumors.

Explore the vital role of antibody-drug conjugates in precision oncology for GI malignancies, focusing on managing payload-dependent toxicities effectively.

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing precision and patient outcomes.

Dr. Filippo Pietrantonio explores the manageable safety profile of amivantamab combined with chemotherapy for metastatic colorectal cancer patients.

Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple myeloma.

Dr. Filippo Pietrantonio explores how amivantamab may transform surgical options for patients with advanced colorectal cancer, enhancing treatment outcomes.

Phase 2 trial shows abemaciclib prolongs disease control in recurrent high‑grade meningioma with NF2/CDK alterations, with 58% PFS at 6 months.

New data from the OrigAMI-1 study highlights promising efficacy and safety of amivantamab with chemotherapy for metastatic colorectal cancer patients.

New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.

A virtual collaborative care model enhances mental health support in oncology, improving patient outcomes and addressing care disparities in underserved populations.

Filippo Pietrantonio discusses overcoming resistance in metastatic colorectal cancer with innovative trials for amivantamab, enhancing treatment efficacy.

Deb Schrag, MD, emphasizes AI's role in enhancing cancer care, addressing early-onset cancers, and improving workforce well-being as she prepares for ASCO leadership.

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

Explore innovative strategies in small cell lung cancer treatment, focusing on bone marrow protection to enhance patient outcomes and treatment durability.

Researchers explore a promising nonchemotherapy treatment for low-grade serous ovarian cancer, combining ribociclib and letrozole to improve patient outcomes.

Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to improving patient outcomes.

Roberto Mina, MD, associate professor of hematology at the Winship Cancer Institute at Emory University, discussed the significance of the patient population of the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.

Experts discuss optimizing NALIRIFOX treatment for metastatic pancreatic cancer, highlighting flexible dosing and early adverse event recognition for better patient outcomes.

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas for multiple myeloma and what will come next now that this data set has been made available.

Rebecca Siegel, MPH, highlights alarming cancer disparities among American Indian, Alaska Native, and Black populations, emphasizing systemic issues over individual choices.

Roberto Mina, MD, discussed the significance of the early outcomes that were reported from the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.

Recent cancer statistics reveal significant survival rate improvements for aggressive cancers, highlighting advancements in treatment and a shift in oncology outcomes.

Dr. Lucio N. Gordan advocates for healthcare reform to protect community oncology, emphasizing site parity and 340B program changes to reduce financial toxicity.

Community oncology significantly reduces cancer care costs while maintaining quality, offering a sustainable solution to financial toxicity for patients.

Lucio N. Gordan discusses the economic burden of financial toxicity in oncology, highlighting its impact on patients and the healthcare system.